---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044545"
form_type: "8-K"
ticker: "NRXS"
cik: "0001933567"
company_name: "Neuraxis, INC"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:19:06.627816+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeurAxis Q3 revenue up 40% to $667K; operating loss narrows 45%; secures $5M investment

## Summary
- Revenue $667K, +40% YoY; unit sales +50%.
- Operating loss $1.7M, improved 45% from $3.0M; net loss $1.8M, improved 80%.
- Expanded insurance coverage to ~35M lives (from 4.5M); new FDA clearance for IB-Stim ages 8-21.
- Received CPT Category I code for PENFS effective Jan 1, 2026.
- Entered $5.0M investment agreement (closing mid-Nov), replacing prior $3.2M commitment; cash on hand $261K.

## SEC filing metadata
- accession: 0001493152-24-044545
- form_type: 8-K
- ticker: NRXS
- cik: 0001933567
- company_name: Neuraxis, INC
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933567/000149315224044545/0001493152-24-044545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933567/000149315224044545/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044545
- JSON: https://secwatch.observer/filing/0001493152-24-044545.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.